EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Nanocarrier strategies to overcome P-glycoprotein-mediated drug resistance in cancer therapy

Andreina Quevedo-Enríquez, Katty Yi Zhang iD, Denisse Yajaira Enriquez, Byron Raul Inapanta, Roxana Noemí Peroni, Christian Rafael Quijia iD

Beilstein Journal of Nanotechnology · 13.07.2026 · 17 · 882-921

DOI: 10.3762/bjnano.17.64 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Beilstein Journal of Nanotechnology, online erschienen am 13.07.2026. Verfasst von Andreina Quevedo-Enríquez und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmacological Research (ININFA UBA-CONICET), Faculty of Pharmacy and Biochemistry, University of Buenos Aires, Junín 956 5° 1113, Auto…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 175 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multidrug resistance (MDR) remains a major barrier to successful cancer chemotherapy, frequently resulting in therapeutic failure, tumor relapses, and poor clinical outcomes. Among the diverse mechanisms underlying MDR, the overexpression of ATP-binding cassette (ABC) transporters, particularly P-glycoprotein (P-gp, encoded by ABCB1) is one of the most extensively studied as it actively effluxes structurally diverse chemotherapeutic agents and reduces intracellular drug exposure below cytotoxic thresholds. In this review, we critically examine recent nanocarrier-based strategies developed to overcome P-gp-mediated resistance across major malignancies, including breast, lung, colorectal, gastric, and prostate cancers. These approaches are categorized according to their principal mechanisms of action: (i) direct functional inhibition of P-gp ATPase activity using small-molecule modulators such as quercetin, ᴅ-α-tocopheryl polyethylene glycol succinate, and tariquidar, (ii) circumvention of membrane efflux through receptor-mediated endocytosis, intracellular trafficking control, or tumor-responsive drug release, and (iii) suppression of transporter expression via co-delivery of siRNA, shRNA, or anti-miRNA payloads targeting ABCB1 regulatory pathways. We further discuss advances in nanoplatform engineering, including lipid-based nanoparticles, polymeric micelles, lipid–polymer hybrid systems, and biomimetic carriers designed to enhance tumor selectivity and intracellular retention. Preclinical evidence consistently demonstrates improved drug accumulation, restored chemosensitivity, and reduced systemic toxicity. Nevertheless, clinical translation remains constrained by tumor heterogeneity, variable biological barriers, large-scale manufacturing requirements, and regulatory complexity. Overall, nanoparticle-mediated modulation of P-gp represents a promising strategy toward precision oncology, although future success will depend on scalable design, mechanistic standardization, and biomarker-guided clinical implementation.

Schlagwörter

Stichwörter der Autor:innen

cancer chemotherapyefflux transportersmultidrug resistance (MDR)nanoparticlessiRNA nanocarrierstumor-targeted therapy

Autor:innen und Institutionen

  • Institute of Pharmacological Research (ININFA UBA-CONICET), Faculty of Pharmacy and Biochemistry, University of Buenos Aires, Junín 956 5° 1113, Autonomous City of Buenos Aires, Argentina.
  • School of Biological Sciences and Engineering, Yachay Tech University, Hda. San José s/n y Proyecto Yachay, Urcuquí 100119, Ecuador.
  • Chair of Pharmacology, Department of Pharmacology, Faculty of Pharmacy and Biochemistry, University of Buenos Aires, Junín 956 5°, 1113, Autonomous City of Buenos Aires, Argentina.

ORCID-Profile: Katty Yi Zhang, Christian Rafael Quijia

Zitieren

APA

Quevedo-Enríquez, A., Zhang, K. Y., Enriquez, D. Y., Inapanta, B. R., Peroni, R. N., & Quijia, C. R. (2026). Nanocarrier strategies to overcome P-glycoprotein-mediated drug resistance in cancer therapy. Beilstein Journal of Nanotechnology, 17, 882-921. https://doi.org/10.3762/bjnano.17.64

Vancouver

Quevedo-Enríquez A, Zhang KY, Enriquez DY, Inapanta BR, Peroni RN, Quijia CR. Nanocarrier strategies to overcome P-glycoprotein-mediated drug resistance in cancer therapy. Beilstein Journal of Nanotechnology. 2026;17:882-921. doi:10.3762/bjnano.17.64

BibTeX
@article{QuevedoEnrquez2026,
  author = {Quevedo-Enríquez, Andreina and Zhang, Katty Yi and Enriquez, Denisse Yajaira and Inapanta, Byron Raul and Peroni, Roxana Noemí and Quijia, Christian Rafael},
  title = {Nanocarrier strategies to overcome P-glycoprotein-mediated drug resistance in cancer therapy},
  journal = {Beilstein Journal of Nanotechnology},
  year = {2026},
  volume = {17},
  pages = {882--921},
  doi = {10.3762/bjnano.17.64}
}
Kostenlos starten →